#6 - AbbVie (NYSE:ABBV)
AbbVie (ABBV) AbbVie (NYSE:ABBV) recently posted an earnings report that beat on both the top line and bottom line. The company posted earnings per share (EPS) of $2.21 on revenue of $8.70 billion. Heading into earnings, analysts were calling for earnings per share (EPS) of $2.19 on revenue of $8.68 billion.
AbbVie has a drug in its pipeline that is being used to treat the coronavirus. But the long-term story for AbbVie is that it has a sound pipeline of oncology and anti-viral drugs. And it has massive cash flow. Both of these are important as the company will be seeing its patents expire on Humira. The company is already seeing atrophy with Humira. European sales declined by 23% in the first quarter. However, in the United States, Humira sales grew 7% to $3.2 billion.
AbbVie stock has a dividend yield of 5.73% and pays out an annual dividend of $4.72 per share. The company has posted annual dividend growth of 22.62% over the last three years and has 47 years of consecutive dividend growth.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $176.95
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 20 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $203.50 (15.0% Upside)
